Lung Function Decline from Adolescence to Young Adulthood in Cystic Fibrosis

Overview

Journal Pediatr Pulmonol

Specialties Pediatrics
Pulmonary Medicine

Date 2012 Jan 14

PMID 22241571

Citations 52

Authors

Stacy L Vandenbranden

Ann McMullen

Michael S Schechter

David J Pasta

Rory L Michaelis

Michael W Konstan

Jeffrey S Wagener

Wayne J Morgan

Susanna A McColley

Affiliations

Soon will be listed here.

Abstract

Background: Despite improving survival in cystic fibrosis (CF) patients, there is a mortality peak in early adulthood. Defining risk factors that predict significant worsening of lung disease in young adulthood may identify opportunities to improve outcomes in adults.

Methods: We identified 4,680 patients in the Epidemiologic Study of Cystic Fibrosis 1994-2005 with data in both adolescence (age 14.0-17.4 years) and young adulthood (age 18.5-22.0 years) and analyzed 2,267 who had ≥5 encounters and ≥5 measurements of forced expiratory volume in 1 second (FEV(1) ) spanning ≥1 year during both adolescence and young adulthood, and ≥1 encounter with weight and height and ≥1 FEV(1) measurement age 17.5-18.5 years. We compared the annualized rates of decline in FEV(1) during adolescence and young adulthood stratified by best FEV(1) around age 18. Logistic regression was used to identify risk factors associated with substantial decline (>20 points) in FEV(1) % predicted in young adulthood.

Results: Annual rate of decline was greater in young adulthood than in adolescence. Risk factors for substantial decline included slower rate of FEV(1) decline, greater FEV(1) variability, faster body mass index (BMI) decline, male sex, chronic inhaled antibiotics, Haemophilus influenzae detection, and absence of multidrug-resistant Pseudomonas aeruginosa in adolescence, and lower than expected FEV(1) and BMI around age 18.

Conclusions: Decline in lung function accelerates in young adults with CF, especially in those with early stage lung disease. Adolescents at risk for substantial decline in lung function in young adulthood have higher FEV(1) and worse nutritional status, among other identifiable risk factors.

Citing Articles

Exploring the dynamics of mixed-species biofilms involving Candida spp. and bacteria in cystic fibrosis.

Gourari-Bouzouina K, Boucherit-Otmani Z, Halla N, Seghir A, Baba Ahmed-Kazi Tani Z, Boucherit K Arch Microbiol. 2024; 206(6):255.

PMID: 38734793 DOI: 10.1007/s00203-024-03967-9.

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy.

Zhou G, Wang Z, Palipana A, Andrinopoulou E, Afonso P, McPhail G Respir Res. 2024; 25(1):187.

PMID: 38678203 PMC: 11056050. DOI: 10.1186/s12931-024-02794-2.

Social-environmental phenotypes of rapid cystic fibrosis lung disease progression in adolescents and young adults living in the United States.

Palipana A, Vancil A, Gecili E, Rasnick E, Ehrlich D, Pestian T Environ Adv. 2023; 14.

PMID: 38094913 PMC: 10718514. DOI: 10.1016/j.envadv.2023.100449.

Prevalence of Anemia and its Relation with Shwachman Score in Children with Cystic Fibrosis.

Afifi M, Hassanzad M, Malek F, Kamfar S, Pourabdollah M, Farnia P Tanaffos. 2023; 22(1):160-166.

PMID: 37920324 PMC: 10618591.

Falling through the Cracks-The Impact of Care Gaps on Lung Function Loss in Cystic Fibrosis.

Love A, Quon B Ann Am Thorac Soc. 2023; 20(9):1235-1236.

PMID: 37655958 PMC: 10502880. DOI: 10.1513/AnnalsATS.202305-459ED.

References

Britto M, Garrett J, Dugliss M, DAESCHNER Jr C, Johnson C, Leigh M . Risky behavior in teens with cystic fibrosis or sickle cell disease: a multicenter study. Pediatrics. 1998; 101(2):250-6. DOI: 10.1542/peds.101.2.250. View

Starner T, Zhang N, Kim G, Apicella M, McCray Jr P . Haemophilus influenzae forms biofilms on airway epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med. 2006; 174(2):213-20. PMC: 2662906. DOI: 10.1164/rccm.200509-1459OC. View

Morgan W, Butler S, Johnson C, Colin A, FitzSimmons S, Geller D . Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol. 1999; 28(4):231-41. DOI: 10.1002/(sici)1099-0496(199910)28:4<231::aid-ppul1>3.0.co;2-2. View

Courtney J, Bradley J, McCaughan J, OConnor T, Shortt C, Bredin C . Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol. 2007; 42(6):525-32. DOI: 10.1002/ppul.20619. View

Konstan M, Morgan W, Butler S, Pasta D, Craib M, Silva S . Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007; 151(2):134-9, 139.e1. DOI: 10.1016/j.jpeds.2007.03.006. View

Liou T, Adler F, FitzSimmons S, Cahill B, Hibbs J, Marshall B . Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001; 153(4):345-52. PMC: 2198936. DOI: 10.1093/aje/153.4.345. View

Rosenfeld M, Davis R, Fitzsimmons S, Pepe M, Ramsey B . Gender gap in cystic fibrosis mortality. Am J Epidemiol. 1997; 145(9):794-803. DOI: 10.1093/oxfordjournals.aje.a009172. View

Liou T, Elkin E, Pasta D, Jacobs J, Konstan M, Morgan W . Year-to-year changes in lung function in individuals with cystic fibrosis. J Cyst Fibros. 2010; 9(4):250-6. PMC: 4102928. DOI: 10.1016/j.jcf.2010.04.002. View

Konstan M, Butler S, Schidlow D, Morgan W, Julius J, Johnson C . Patterns of medical practice in cystic fibrosis: part II. Use of therapies. Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Pediatr Pulmonol. 1999; 28(4):248-54. DOI: 10.1002/(sici)1099-0496(199910)28:4<248::aid-ppul3>3.0.co;2-n. View

10.

Konstan M, Wagener J, Pasta D, Millar S, Jacobs J, Yegin A . Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol. 2011; 46(6):545-53. PMC: 4109161. DOI: 10.1002/ppul.21388. View

11.

Johnson C, Butler S, Konstan M, Morgan W, Wohl M . Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest. 2003; 123(1):20-7. DOI: 10.1378/chest.123.1.20. View

12.

Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W . Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32(9):1626-31. PMC: 2732133. DOI: 10.2337/dc09-0586. View

13.

Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R . Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34(2):91-100. DOI: 10.1002/ppul.10127. View

14.

Sawyer S, Rosier M, Phelan P, Bowes G . The self-image of adolescents with cystic fibrosis. J Adolesc Health. 1995; 16(3):204-8. DOI: 10.1016/1054-139X(94)00071-L. View

15.

Packe G, Hodson M . Changes in spirometry during consecutive admissions for infective pulmonary exacerbations in adolescent and adult cystic fibrosis. Respir Med. 1992; 86(1):45-8. DOI: 10.1016/s0954-6111(06)80147-2. View

16.

Ren C, Pasta D, Rasouliyan L, Wagener J, Konstan M, Morgan W . Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr. 2008; 153(6):746-51. DOI: 10.1016/j.jpeds.2008.07.010. View

17.

Sharma R, Florea V, Bolger A, Doehner W, Florea N, Coats A . Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax. 2001; 56(10):746-50. PMC: 1745930. DOI: 10.1136/thorax.56.10.746. View

18.

Hankinson J, Odencrantz J, Fedan K . Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999; 159(1):179-87. DOI: 10.1164/ajrccm.159.1.9712108. View

19.

Verma N, Bush A, Buchdahl R . Is there still a gender gap in cystic fibrosis?. Chest. 2005; 128(4):2824-34. DOI: 10.1378/chest.128.4.2824. View

20.

Parker H . Transition and transfer of patients who have cystic fibrosis to adult care. Clin Chest Med. 2007; 28(2):423-32. DOI: 10.1016/j.ccm.2007.02.007. View